Dr Reddy's, RDIF commence clinical trials for Covid vaccine Sputnik V in India

The phase 2 trial involves 100 volunteers, according to information shared by Dr. Reddy's.

Published: 01st December 2020 07:57 PM  |   Last Updated: 01st December 2020 10:06 PM   |  A+A-

A volunteer receives an injection at the Chris Hani Baragwanath hospital in Soweto, Johannesburg, as part of Africa's first participation in a COVID-19 vaccine trial developed at the University of Oxford in Britain. (File | AP)

For representational purpose. (File photo | AP)

By Express News Service

HYDERABAD: City-based Dr. Reddy’s Laboratories and the Russian Direct Investment Fund (RDIF) on Tuesday announced that they have commenced the adaptive Phase 2/3 clinical trials in India for the Sputnik V vaccine against Covid-19, following necessary clearances from the Central Drugs Laboratory, Kasauli. 

The phase 2 trial involves 100 volunteers, according to information shared by Dr. Reddy's.

These clinical trials will be a multicenter and randomized controlled study, which will include a safety and immunogenicity study and are being conducted by JSS Medical Research as the clinical research partner.

In a press release on Tuesday, Dr. Reddy's informed that it has partnered with the Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT) for advisory support and to use BIRAC’s clinical trial centres for the vaccine.

G V Prasad, Co-chairman and Managing Director, Dr. Reddy’s Laboratories said, “This is another significant step as we continue to collaborate with multiple entities along with the government bodies to fast-track the process for launching the vaccine in India. We are working towards making the vaccine available with a combination of import and indigenous production model.”

Dr. Reddy's and RDIF had received the clearance from the Drugs Controller General of India in October to conduct an adaptive phase 2/3 human clinical trial for the Sputnik V vaccine in India. They entered into a partnership to conduct clinical trials of the Sputnik V vaccine and its distribution in the country, as part of which the RDIF will supply 100 million doses of the vaccine to Dr. Reddy’s upon regulatory approval in India.

Stay up to date on all the latest Nation news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp